Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Sensitivity and specificity
研究概览
简要总结
This pilot clinical trial studies ultra-high field magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) techniques in diagnosing breast cancer. New diagnostic procedures may be a more sensitive way to detect breast cancer.
详细描述
PRIMARY OBJECTIVES:
I. To implement quantitative dynamic contrast-enhanced (DCE)-MRI, diffusion-weighted (DW)-MRI, 31 phosphorus (31P) MRS, magnetization transfer (MT)-MRI, chemical exchange saturation transfer (CEST)-MRI, and high-resolution structural imaging at 7 Tesla in patients for diagnosing breast tumors.
OUTLINE:
Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. Diagnostic performance of one, or a combination, of these metrics will be investigated in the context of breast cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subjects must have signed an approved consent form
- •Must be at least 18 years old
- •Subjects must have undergone x-ray mammography and/or ultrasonography
- •Subjects must have undergone standard clinical (1.5 Tesla) MRI as part of their standard-of-care diagnostic workup:
- •To evaluate the extent of disease for a previously diagnosed cancer, or
- •To evaluate a clinically suspected lesion that was occult on mammography and/or ultrasonography, or
- •Because the patient is considered high-risk (according to National Comprehensive Cancer Network [NCCN] criteria)
- •Subjects must be classified Breast Imaging-Reporting and Data System (BI-RADS) 4 or 5
- •Subjects must be scheduled for diagnostic biopsy to evaluate a lesion that measures >10 mm in the greatest dimension.
排除标准
- •Subjects who have distant metastases
- •Subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means (e.g., cochlear implants, pacemakers, neurostimulators, biostimulators, electronic infusion pumps, aneurysm clip, etc), because such devices may be displaced or malfunction
- •Subjects who have any type of ferromagnetic bioimplant that could potentially be displaced by the magnetic field of the MRI scanner
- •Subjects who may have shrapnel imbedded in their bodies (such as from war wounds), metal workers, and machinists (potential for metallic fragments in or near the eyes)
- •Subjects with a history of renal disease (including renal cancer), diabetes, or human immunodeficiency virus (HIV)
- •Creatinine >= 1.5 times upper limit of normal
- •Estimated glomerular filtration rate < 30 mL/min
- •Subjects who are pregnant or breast-feeding; the MRI Procedure Screening Form will be used to identify and exclude subjects who are pregnant or breastfeeding; a urine pregnancy test/or serum human chorionic gonadotropin (HCG) will also be performed for pre-menopausal women who are not using contraceptives
- •Subjects who have exhibited past allergic or other adverse reactions in response to intravenous injection of Magnevist (gadopentetate dimeglumine) or other gadolinium-containing contrast agents
- •Subjects who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe vertigo when they are moved into the magnet bore
- •Subjects incapable of giving informed written consent, for the following reasons:
- •Inability to adhere to the experimental protocols for any reason
- •Inability to communicate with the research team
- •Limited ability to give informed consent due to mental disability, altered mental status, confusion, or psychiatric disorders
- •Prisoners or other individuals deemed to be susceptible to coercion
结局指标
主要结局
Sensitivity and specificity
时间窗: At time of imaging procedure
Ninety-percent simultaneous confidence rectangles for sensitivity and specificity will be constructed at the 25th, 50th (median), and 75th percentiles of the model predicted probability of disease.
次要结局
- Pathological disease status(At time of imaging procedure)
研究者
Thomas Yankeelov
Director of Cancer Imaging Research, Vanderbilt University Institute of Imaging Science (VUIIS); Associate Professor of Radiology and Radiological Sciences, Biomedical Engineering, Physics and Astronomy, and Cancer Biology;
Vanderbilt-Ingram Cancer Center